Status:
ACTIVE_NOT_RECRUITING
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Multiple Sclerosis (MS)
Eligibility:
All Genders
18-99 years
Brief Summary
SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol.
Detailed Description
This is a non-interventional, prospective (primary data), multicenter study conducted in metropolitan France. The primary objective of this study is to describe the quality of life of MS patients afte...
Eligibility Criteria
Inclusion
- Male or female, 18 years of age or older
- Patient with confirmed MS diagnosis
- Patient initiating treatment with ofatumumab for the first time
- Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study
- Patient not opposed to participation in this study
- Patient willing and able to complete patient questionnaires
Exclusion
- 1\. Patient treated with ofatumumab in the context of a clinical trial
Key Trial Info
Start Date :
December 21 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2026
Estimated Enrollment :
302 Patients enrolled
Trial Details
Trial ID
NCT06157086
Start Date
December 21 2023
End Date
July 31 2026
Last Update
December 22 2025
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Angers, France, France, 49933
2
Novartis Investigative Site
Paris, France, France, F-75571
3
Novartis Investigative Site
Agen, France, 47923
4
Novartis Investigative Site
Altkirch, France, 68130